Zymeworks

Zymeworks’ antibody technology platforms combine protein engineering and drug chemistry to create therapeutics for hard-to-treat diseases.

The company’s pipeline includes clinical and preclinical candidates for difficult-to-treat cancers and serious diseases, both owned and partnered.

Zymeworks supports National Stomach Cancer Month in November by collaborating with advocacy groups like Debbie’s Dream Foundation and Gastric Cancer Foundation to raise awareness.

Zymeworks will present data on ZW1528 at the 2025 European Respiratory Society Congress in Amsterdam.

We are pleased to present preclinical data on ZW171 in a poster presentation at the annual SITC Conference, taking place November 6-10 in Houston, TX. The poster presentation titled “Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3” (Abstract #: 1062) […]

About us Zymeworks is a global biotechnology company managing a diversified portfolio of healthcare assets and developing novel, multifunctional biotherapeutics for difficult-to-treat diseases. Our strategy combines commercial and near-commercial assets with in-house research and development capabilities to support long-term value creation and advance innovative medicines. Our portfolio includes YUPELRI (revefenacin), Ziihera (zanidatamab-hrii), a HER2-targeted bispecific […]

Zymeworks develops antibody-based therapeutics using multispecifics and drug conjugates, supported by proprietary platforms and global partnerships.

The company’s strategy integrates royalty growth, acquisitions, and internal innovation to build a diversified healthcare portfolio.

The company partners with collaborators to accelerate development of multifunctional therapeutics for broader patient access.

Contact us Corporate Head Office Zymeworks Inc. 114 East 4th Avenue, Suite 800Vancouver, BC, Canada V5T 1G4 T. (604) 678-1388F. (206) 237-0892 U.S. Offices Zymeworks Biopharmaceuticals Inc. 777 108th Ave NE, Suite 1700Bellevue, WA, 98004 T. (206) 237-1030 Zymeworks Biopharmaceuticals Inc. 110 Greene St, Suite 300New York, NY, 10012 Asia Pacific Office Zymeworks Lifesciences Pte. Ltd. Bridge+ […]

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases

For inquiries about zanidatamab (ZW25) clinical trial information, please contact medinfo@zymeworks.com

Zymeworks is a clinical-stage biotech company developing treatments for difficult-to-treat diseases, including cancer and autoimmune conditions.

Zymeworks presents updated Phase 1 trial data for **ZW191**, its folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the **ESMO Congress 2026**. The findings stem from the randomized dose-optimization phase of the ongoing study, evaluating safety and efficacy in oncology patients. Zymeworks continues advancing its pipeline of novel biotherapeutics alongside its licensed healthcare assets.

Oct 2026Zymeworks Inc.News article

Zymeworks secures an $813 million global licensing and collaboration agreement with Roche for its T cell engager ZW209, targeting DLL3. The deal drives a 5.5% premarket stock rise for Zymeworks. Roche gains access to ZW209, a potential immunotherapy candidate in development.

Oct 2026Yahoo FinanceNews article

Roche licenses Zymeworks’ ZW209 cancer therapy and funds its development, securing global rights in an agreement potentially worth up to $813 million. Zymeworks will lead the Phase 1a clinical trial under the partnership. The deal combines Roche’s resources with Zymeworks’ antibody-based treatment pipeline.

Oct 2026Contract PharmaNews article

Zymeworks grants Roche exclusive global rights to develop and commercialize **ZW209**, a trispecific T cell engager targeting **DLL3**, under a new license and collaboration agreement. The partnership covers research, development, and commercialization of the asset, expanding Roche’s oncology pipeline with Zymeworks’ novel biotherapeutic. Zymeworks retains its portfolio of licensed healthcare assets while advancing its own pipeline of multifunctional biotherapeutics.

Oct 2026Macau BusinessNews article